Primary Cells Market Insights Industry Size, Growth, Opportunity, With Global Forecast To 2030

Comments · 158 Views

This is expecting the primary cells market to register a growth of 10.40% CAGR and reaching a market valuation that sums up to USD 1,085.82 Million by the end of the forecast period

Primary Cells Market Overview:

Primary human cells are necessary for some medical purposes like research. Market Research Future (MRFR) has published a research report about the global primary cells market report that has predicted significant growth with 10.40% CAGR (Compound Annual Growth Rate) for this market between 2023 and 2030. The key factors that drive this market are growing cancer research, increasing demand for monoclonal antibodies, rapid growth in biotechnology and biopharmaceutical industries, rising healthcare expenditure, and various other advantages. However, factors that can obstruct the growth of this market include the high cost of advanced primary cells and risk of contamination.

 

Segmentation:

The global primary cells market insights trends has been segmented on the basis of the end user, origin, type, and lastly region. Based on end users, this market has been segmented into research institutes and life science research companies. On the basis of origin, the market has been segmented into gastrointestinal cells, hematopoietic cells, heart cells, liver cells, lung cells, renal cells, skeletal and muscle cells, skin cells, and others. By type, the market has been segmented into animal; primary and human primary cells. Animal primary cells are isolated and purified from qualified laboratory animal tissues. Primary human cells are directly cultured from their source organ tissue or blood cells.

The regional segmentation of the global primary cells market covers the Americas (North America South America), Europe, Asia-Pacific, and the Middle East and Africa (MEA). In the Americas, North America is a bigger market than South America due to growing government funding in research, increasing prevalence of cancer, the presence of a well-established healthcare system, technological advancement, and advanced medical facilities. In this region, the biggest markets are the United States of America (USA) and Canada.

The primary cells market in Europe has been segmented into Western Europe and Eastern Europe. Due to reasons same as the Americas, Western Europe is a bigger market than Eastern Europe. Government support towards research and development and growing prevalence of chronic diseases such as cancer are driving the market in this region. In Europe, the maximum market revenue comes from France, Germany, Italy, Spain, and the United Kingdom (UK), followed by the rest of Western Europe.

Regional Analysis

In the Asia Pacific reason, the market is driven by factors including growing pharmaceutical outsourcing, increasing government funding in the life sciences sector, rapidly expanding biopharmaceutical industries in the region and rising prevalence of cancer. India and China have made a maximum contribution to the market by establishing the research institutes promoting cell-based research. Other important markets in this region include Australia, Japan, and South Korea, followed by the rest of Asia-Pacific.

The MEA region is a small market due to lack of awareness about biosurgery products, lack of education, lack of technological development, poor healthcare, and healthcare not considered a priority by most governments.

Key Players

The key players in the global primary cells market include ALLCells (USA), American Type Culture Collection (ATCC) (USA), Axol Biosciences (UK), Cell Biologics (USA), Lonza (Switzerland), Merck KGaA (Germany), Promocell (Germany), STEMCELL Technologies (Canada), Thermo Fisher Scientific (USA), and ZenBio, Inc. (USA).

Latest Industry News

  • Science Exchange, the leading marketplace for outsourced RD™, is collaborating with AUM BioTech, an emerging Philadelphia-based startup, to advance genetic research and significantly cut short drug discovery and development time. 31 JUL 2018
  • The FDA has granted accelerated approval to single-agent nivolumab (Opdivo) for the treatment of patients with small cell lung cancer (SCLC) with disease progression following platinum-based chemotherapy and one other line of therapy. 17 AUG 2018

 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]

Comments